Kidney function monitoring and trajectories in patients with atrial fibrillation.
Atrial fibrillation
Epidemiology
Kidney impairment
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
08
07
2022
accepted:
24
07
2023
pubmed:
14
8
2023
medline:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Atrial fibrillation (AF) and chronic kidney disease (CKD) frequently co-exist. The frequency of kidney monitoring and range of kidney function in patients with AF in clinical practice are uncertain. All adult Albertans with AF between 2008 and 2017 were identified using ICD-9 and -10 codes 427.3 and I48. Kidney Disease Improving Global Outcomes (KDIGO) risk categories were defined using eGFR by the Chronic Kidney Disease Epidemiology Collaborative equation and albuminuria results within 6 months of eGFR measurement. eGFR trajectories were compared from baseline to maximum value within the following year. Among 105,946 patients with AF, 16.0% were KDIGO category G1 (eGFR ≥ 90), 49.0% G2 (60-89.9), 19.8% G3a (45-59.9), 11.4% G3b (30-44.9), and G4 3.8% (15-29.9). Albuminuria was normal/mild 83.4%, moderate 11.7%, and severe 4.9%. Kidney monitoring was more common among people with lower eGFR and worse albuminuria, from approximately twice annually for G1-2/A1-2 to 8 times annually in stage G4A3. Approximately 60-80% of patients received guideline-recommended monitoring, consistent across KDIGO stages. With lower baseline eGFR, annual change in eGFR decreased while the relative proportion of patients who worsened compared to improved increased: for baseline eGFR 60-89.9, 16.7% worsened vs 6.7% improved, but for eGFR 30-44.9, 8.8% worsened but only 1.0% improved. The frequency of kidney function monitoring in patients with AF increased with worsening KDIGO risk category and adhered to KDIGO guidelines in approximately three quarters of patients. A minority of patients had moderate to severe eGFR impairment, of whom most remained stable over 1 year.
Sections du résumé
BACKGROUND
BACKGROUND
Atrial fibrillation (AF) and chronic kidney disease (CKD) frequently co-exist. The frequency of kidney monitoring and range of kidney function in patients with AF in clinical practice are uncertain.
METHODS
METHODS
All adult Albertans with AF between 2008 and 2017 were identified using ICD-9 and -10 codes 427.3 and I48. Kidney Disease Improving Global Outcomes (KDIGO) risk categories were defined using eGFR by the Chronic Kidney Disease Epidemiology Collaborative equation and albuminuria results within 6 months of eGFR measurement. eGFR trajectories were compared from baseline to maximum value within the following year.
RESULTS
RESULTS
Among 105,946 patients with AF, 16.0% were KDIGO category G1 (eGFR ≥ 90), 49.0% G2 (60-89.9), 19.8% G3a (45-59.9), 11.4% G3b (30-44.9), and G4 3.8% (15-29.9). Albuminuria was normal/mild 83.4%, moderate 11.7%, and severe 4.9%. Kidney monitoring was more common among people with lower eGFR and worse albuminuria, from approximately twice annually for G1-2/A1-2 to 8 times annually in stage G4A3. Approximately 60-80% of patients received guideline-recommended monitoring, consistent across KDIGO stages. With lower baseline eGFR, annual change in eGFR decreased while the relative proportion of patients who worsened compared to improved increased: for baseline eGFR 60-89.9, 16.7% worsened vs 6.7% improved, but for eGFR 30-44.9, 8.8% worsened but only 1.0% improved.
CONCLUSION
CONCLUSIONS
The frequency of kidney function monitoring in patients with AF increased with worsening KDIGO risk category and adhered to KDIGO guidelines in approximately three quarters of patients. A minority of patients had moderate to severe eGFR impairment, of whom most remained stable over 1 year.
Identifiants
pubmed: 37578638
doi: 10.1007/s10157-023-02389-z
pii: 10.1007/s10157-023-02389-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
981-989Subventions
Organisme : Heart and Stroke Foundation of Canada
ID : F16-03786
Informations de copyright
© 2023. The Author(s), under exclusive licence to The Japanese Society of Nephrology.
Références
Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161–9.
doi: 10.1016/S0140-6736(16)30968-0
pubmed: 27515684
Hawkins NM, Jhund PS, Pozzi A, O’Meara E, Solomon SD, Granger CB, et al. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail. 2016;18(9):1162–71.
doi: 10.1002/ejhf.614
pubmed: 27594177
Inohara T, Holmes DN, Pieper K, Blanco RG, Allen LA, Fonarow GC, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020;106(5):358–64.
doi: 10.1136/heartjnl-2019-315792
pubmed: 31911503
Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–90.
doi: 10.1016/j.jacc.2017.03.600
pubmed: 28595692
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847–948.
doi: 10.1016/j.cjca.2020.09.001
pubmed: 33191198
Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol. 2009;10:30.
doi: 10.1186/1471-2369-10-30
pubmed: 19840369
pmcid: 2770500
Hawkins NM, Daniele PR, Humphries KH, Ezekowitz JA, McAlister FA, Sandhu RK, et al. Empirical insights when defining the population burden of atrial fibrillation and oral anticoagulation utilization using administrative data. Can J Cardiol. 2019;35(10):1412–5.
doi: 10.1016/j.cjca.2019.05.009
pubmed: 31473069
Diabetes Canada Clinical Practice Guidelines Expert Consortium, McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic kidney disease in diabetes. Can J Diabetes. 2018;42 Suppl 1:S201–9.
American Diabetes Association. 10. Microvascular Complications and Foot Care. Diabetes Care. 2017;40(Suppl 1):S88–98.
doi: 10.2337/dc17-S013
Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65(23):2481–93.
doi: 10.1016/j.jacc.2015.03.577
pubmed: 26065986
Eriksen BO, Ingebretsen OC. In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression. Kidney Int. 2007;72(10):1242–8.
doi: 10.1038/sj.ki.5002472
pubmed: 17687256
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51.
doi: 10.1161/CIR.0000000000000665
pubmed: 30686041
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93.
doi: 10.1093/eurheartj/ehy136
pubmed: 29562325
Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inform Decis Making. 2015;15:31.
doi: 10.1186/s12911-015-0155-5
McAlister FA, Wiebe N, Jun M, Sandhu R, James MT, McMurtry MS, et al. Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease? Can J Cardiol. 2017;33(2):243–52.
doi: 10.1016/j.cjca.2016.08.018
pubmed: 27956042
Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J. 2013;34(46):3572–9.
doi: 10.1093/eurheartj/eht328
pubmed: 23966309
Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L, et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep. 2016;6:30271.
doi: 10.1038/srep30271
pubmed: 27466080
pmcid: 4964613
Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, et al. Influence of kidney function estimation methods on eligibility for edoxaban population impact of the US Food and Drug Administration’s approach for its product labeling. Circulation. 2016;134(15):1122–4.
doi: 10.1161/CIRCULATIONAHA.116.024333
pubmed: 27753615
Suzuki S, Sagara K, Otsuka T, Kanou H, Matsuno S, Uejima T, et al. Estimated glomerular filtration rate and proteinuria are associated with persistent form of atrial fibrillation: analysis in Japanese patients. J Cardiol. 2013;61(1):53–7.
doi: 10.1016/j.jjcc.2012.07.016
pubmed: 23085035
Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol. 2013;6(5):868–74.
doi: 10.1161/CIRCEP.113.000869
pubmed: 24047706
Roldan V, Marin F, Manzano-Fernandez S, Fernandez H, Gallego P, Valdes M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109(5):956–60.
doi: 10.1160/TH13-01-0054
pubmed: 23572113
Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2014;145(6):1370–82.
doi: 10.1378/chest.13-2103
pubmed: 24356875
Bonde AN, Lip GY, Kamper AL, Fosbol EL, Staerk L, Carlson N, et al. Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: an observational cohort study. Stroke. 2016;47(11):2707–13.
doi: 10.1161/STROKEAHA.116.014422
pubmed: 27758943
Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363–9.
doi: 10.1161/CIRCULATIONAHA.108.816082
pubmed: 19255343
pmcid: 2733238
McManus DD, Corteville DC, Shlipak MG, Whooley MA, Ix JH. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009;104(11):1551–5.
doi: 10.1016/j.amjcard.2009.07.026
pubmed: 19932791
pmcid: 2796571
Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111(8):1159–64.
doi: 10.1016/j.amjcard.2012.12.045
pubmed: 23337836
Brendorp B, Pedersen O, Torp-Pedersen C, Sahebzadah N, Kober L. A benefit-risk assessment of class III antiarrhythmic agents. Drug Saf. 2002;25(12):847–65.
doi: 10.2165/00002018-200225120-00003
pubmed: 12241126
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–8.
doi: 10.1001/jama.289.7.871
pubmed: 12588271
Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(12):2307–24.
doi: 10.1097/HJH.0000000000002187
pubmed: 31688290
Wu D, Mansoor G, Kempf C, Schwalm MS, Chin J. Renal function, attributes and coagulation treatment in atrial fibrillation (R-FACT Study): retrospective, observational, longitudinal cohort study of renal function and antithrombotic treatment patterns in atrial fibrillation patients with documented eGFR in real-world clinical practices in Germany. Int J Clin Pract. 2014;68(6):714–24.
doi: 10.1111/ijcp.12379
pubmed: 24499317
Yao RJR, Andrade JG, Deyell MW, Jackson H, McAlister FA, Hawkins NM. Sensitivity, specificity, positive and negative predictive values of identifying atrial fibrillation using administrative data: a systematic review and meta-analysis. Clin Epidemiol. 2019;11:753–67.
doi: 10.2147/CLEP.S206267
pubmed: 31933524
pmcid: 6712502